WASHINGTON, D.C. – President Donald Trump signed an executive order Saturday directing federal agencies to fast-track the development and approval of psychedelic medications for medical treatment purposes.
The directive instructs the Food and Drug Administration to prioritize the review process for substances like ibogaine, which veterans’ organizations believe could provide effective treatment for post-traumatic stress disorder.
During a ceremony held in the Oval Office, federal administrators explained that these policy changes would create a pathway for hallucinogenic substances – currently classified as illegal drugs – to receive new regulatory status following successful medical trials. The president also committed $50 million in federal funding specifically for ibogaine research initiatives.
